HK1081451A1 - Medicinal composition - Google Patents

Medicinal composition

Info

Publication number
HK1081451A1
HK1081451A1 HK06101846A HK06101846A HK1081451A1 HK 1081451 A1 HK1081451 A1 HK 1081451A1 HK 06101846 A HK06101846 A HK 06101846A HK 06101846 A HK06101846 A HK 06101846A HK 1081451 A1 HK1081451 A1 HK 1081451A1
Authority
HK
Hong Kong
Prior art keywords
medicinal composition
medicinal
composition
Prior art date
Application number
HK06101846A
Other languages
English (en)
Inventor
Shusei Ito
Akio Miwa
Mari Nakano
Original Assignee
Taisho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taisho Pharmaceutical Co Ltd filed Critical Taisho Pharmaceutical Co Ltd
Publication of HK1081451A1 publication Critical patent/HK1081451A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK06101846A 2002-05-28 2006-02-13 Medicinal composition HK1081451A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002154624 2002-05-28
PCT/JP2003/006596 WO2003099288A1 (fr) 2002-05-28 2003-05-27 Composition medicinale

Publications (1)

Publication Number Publication Date
HK1081451A1 true HK1081451A1 (en) 2006-05-19

Family

ID=29561374

Family Applications (1)

Application Number Title Priority Date Filing Date
HK06101846A HK1081451A1 (en) 2002-05-28 2006-02-13 Medicinal composition

Country Status (10)

Country Link
US (1) US6818662B2 (ja)
EP (1) EP1508332A4 (ja)
JP (1) JP4475405B2 (ja)
CN (1) CN1290506C (ja)
AU (1) AU2003241800B2 (ja)
CA (1) CA2486571C (ja)
HK (1) HK1081451A1 (ja)
MX (1) MXPA04011777A (ja)
RU (1) RU2313346C2 (ja)
WO (1) WO2003099288A1 (ja)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008230968A (ja) * 2005-06-30 2008-10-02 Taisho Pharmaceutical Co Ltd 脳梗塞治療用の医薬
US7744904B1 (en) * 2005-09-26 2010-06-29 B.B. Scientific L.L.C. Stabilization of Clostridium botulinum neurotoxin complex
WO2008034011A2 (en) 2006-09-13 2008-03-20 Mcw Research Foundation, Inc. Methods of modulating cell proliferation and cyst formation in polycystic kidney and liver diseases
BRPI0916689A2 (pt) 2008-07-28 2015-11-17 Takeda Pharmaceutical composição farmacêutica estabilizada, preparação sólida, e, métodos para estabilizar uma composição farmacêutica, e para estabilizar uma preparação sólida.

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3502720A (en) * 1963-12-20 1970-03-24 Schering Ag N-(2-methyl-4-chlorophenyl)-formamidines
US4237168A (en) * 1979-06-11 1980-12-02 The Dow Chemical Company N-(4-Chloro-2-methylphenyl)-N-hydroxy methanimidamide and its pesticidal use
DE3346123A1 (de) 1983-12-21 1985-06-27 Janssen Pharmaceutica, N.V., Beerse Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
JPH092977A (ja) 1995-06-21 1997-01-07 Dai Ichi Seiyaku Co Ltd 経口投与用医薬組成物
US6395781B1 (en) * 1998-02-26 2002-05-28 Mcw Research Foundation 20-HETE antagonists and agonists
US6864254B1 (en) 1999-11-01 2005-03-08 Taisho Pharmaceutical Co., Ltd. Inhibitor for 20-hete-yielding enzyme
US7214714B2 (en) 2001-04-26 2007-05-08 Taisho Pharmaceutical Co. Ltd. 20-hydroxyeicosatetraenoic acid production inhibitors

Also Published As

Publication number Publication date
AU2003241800B2 (en) 2007-04-19
EP1508332A1 (en) 2005-02-23
JPWO2003099288A1 (ja) 2005-09-22
US6818662B2 (en) 2004-11-16
JP4475405B2 (ja) 2010-06-09
CA2486571A1 (en) 2003-12-04
CA2486571C (en) 2010-04-27
RU2313346C2 (ru) 2007-12-27
EP1508332A4 (en) 2010-01-13
WO2003099288A1 (fr) 2003-12-04
MXPA04011777A (es) 2005-03-31
US20030225032A1 (en) 2003-12-04
AU2003241800A1 (en) 2003-12-12
CN1290506C (zh) 2006-12-20
CN1655790A (zh) 2005-08-17
RU2004138299A (ru) 2005-06-10

Similar Documents

Publication Publication Date Title
AU2003291103A8 (en) Pharmaceutical composition
GB2389530B (en) Pharmaceutical compositions
AU2003244650A8 (en) Medicinal compounds
GB0204719D0 (en) Medicinal compounds
GB0220730D0 (en) Medicinal compounds
IL164547A0 (en) Pharmaceutical composition
GB2391473B (en) Pharmaceutical compositions
AU2003250372A8 (en) Pharmaceutical composition
HK1093896A1 (en) Medicinal composition
GB0229258D0 (en) Medicinal compositions
EP1600445A4 (en) CURATIVE PREPARATION
GB0213481D0 (en) Pharmaceutical compositions
HK1081451A1 (en) Medicinal composition
HK1065477A1 (en) Pharmaceutical composition
HK1062274A1 (en) Medicinal composition
PL370907A1 (en) Pharmaceutical compositions
EP1547593A4 (en) MEDICINAL COMPOSITION
GB0217703D0 (en) Pharmaceutical composition
GB0213267D0 (en) Pharmaceutical composition
GB0225042D0 (en) Pharmaceutical composition
GB0227342D0 (en) Pharmaceutical composition
GB0211448D0 (en) Pharmaceutical composition
GB0228111D0 (en) Pharmaceutical composition
GB0213306D0 (en) Pharmaceutical composition
GB0220095D0 (en) Pharmaceutical composition

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20110527